JP7183180B2 - Ｃ５結合性を欠失したコバーシンバリアント - Google Patents

Ｃ５結合性を欠失したコバーシンバリアント Download PDF

Info

Publication number
JP7183180B2
JP7183180B2 JP2019556928A JP2019556928A JP7183180B2 JP 7183180 B2 JP7183180 B2 JP 7183180B2 JP 2019556928 A JP2019556928 A JP 2019556928A JP 2019556928 A JP2019556928 A JP 2019556928A JP 7183180 B2 JP7183180 B2 JP 7183180B2
Authority
JP
Japan
Prior art keywords
seq
modified
replaced
polypeptide
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517260A5 (enExample
JP2020517260A (ja
Inventor
アンドリュー ナン，マイルズ
Original Assignee
ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴォリューション イミュノ ファーマシューティカルズ エスエイ filed Critical ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Publication of JP2020517260A publication Critical patent/JP2020517260A/ja
Publication of JP2020517260A5 publication Critical patent/JP2020517260A5/ja
Application granted granted Critical
Publication of JP7183180B2 publication Critical patent/JP7183180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019556928A 2017-04-21 2018-04-20 Ｃ５結合性を欠失したコバーシンバリアント Active JP7183180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
PCT/EP2018/060240 WO2018193121A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding

Publications (3)

Publication Number Publication Date
JP2020517260A JP2020517260A (ja) 2020-06-18
JP2020517260A5 JP2020517260A5 (enExample) 2021-05-27
JP7183180B2 true JP7183180B2 (ja) 2022-12-05

Family

ID=58795719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556928A Active JP7183180B2 (ja) 2017-04-21 2018-04-20 Ｃ５結合性を欠失したコバーシンバリアント

Country Status (12)

Country Link
US (2) US11214602B2 (enExample)
EP (1) EP3612207B1 (enExample)
JP (1) JP7183180B2 (enExample)
KR (1) KR102630702B1 (enExample)
CN (1) CN110799207B (enExample)
AU (1) AU2018253961B2 (enExample)
CA (1) CA3060336A1 (enExample)
ES (1) ES2980279T3 (enExample)
GB (1) GB201706406D0 (enExample)
IL (1) IL269856B2 (enExample)
PL (1) PL3612207T3 (enExample)
WO (1) WO2018193121A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023040169A (ja) * 2017-04-21 2023-03-22 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511632A (ja) 2008-02-05 2011-04-14 ナチュラル・エンバイロンメント・リサーチ・カウンシル エイコサノイドによって媒介される疾患及び症状の治療
JP2012516694A (ja) 2009-02-05 2012-07-26 ナチュラル・エンバイロンメント・リサーチ・カウンシル 補体阻害物質としての改変ｏｍｃｉ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077709A1 (en) * 2000-03-21 2003-04-24 Masazumi Kamohara Novel leukotriene B4 receptor
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511632A (ja) 2008-02-05 2011-04-14 ナチュラル・エンバイロンメント・リサーチ・カウンシル エイコサノイドによって媒介される疾患及び症状の治療
JP2012516694A (ja) 2009-02-05 2012-07-26 ナチュラル・エンバイロンメント・リサーチ・カウンシル 補体阻害物質としての改変ｏｍｃｉ

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023040169A (ja) * 2017-04-21 2023-03-22 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
JP7600278B2 (ja) 2017-04-21 2024-12-16 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン

Also Published As

Publication number Publication date
IL269856B2 (en) 2024-09-01
CN110799207A (zh) 2020-02-14
EP3612207C0 (en) 2024-04-10
PL3612207T3 (pl) 2024-09-23
GB201706406D0 (en) 2017-06-07
US11214602B2 (en) 2022-01-04
EP3612207B1 (en) 2024-04-10
EP3612207A1 (en) 2020-02-26
WO2018193121A1 (en) 2018-10-25
CN110799207B (zh) 2024-05-03
IL269856A (en) 2019-11-28
AU2018253961A1 (en) 2019-10-31
IL269856B1 (en) 2024-05-01
US20230002456A1 (en) 2023-01-05
JP2020517260A (ja) 2020-06-18
KR20190141163A (ko) 2019-12-23
US20200385434A1 (en) 2020-12-10
ES2980279T3 (es) 2024-09-30
KR102630702B1 (ko) 2024-01-29
CA3060336A1 (en) 2018-10-25
AU2018253961B2 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
US11214602B2 (en) Coversin variants lacking C5 binding
EP3047024B1 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
EP2678355B1 (fr) Nouveaux fragments d'il-33 superactifs et leurs utilisations
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
JP7144402B2 (ja) Ｍｇ５３突然変異体、その作製方法、およびその使用
JP2016526885A (ja) Ｃｔｌａ−４に対する親和性が改善したｃｄ８６バリアント
AU2009211257A1 (en) Treatment of diseases and conditions mediated by eicosanoids
IL181898A (en) Interleukin-4 (il-4) and interleukin-9 (il-9) chimeric mutein receptor antagonists, compositions comprising them, polynucleotide encoding them, methods of their production and uses thereof
DK2393831T3 (en) MODIFIED OMCI AS COMPLEMENT INHIBITOR
AU730738B2 (en) Antimicrobially active polypeptides
CN114380919B (zh) 经修饰的il-2分子及其用途
KR20220137876A (ko) 조직 재생의 촉진에 유용한 hmgb1과 관련된 폴리펩티드, 이를 포함하는 조성물, 및 이들의 용도
WO2008145013A1 (zh) 包含cd13靶向肽和力达霉素的融合蛋白
WO2021081301A1 (en) Computational design of alpha(v) beta (6) integrin binding proteins
JP5982394B2 (ja) ＭＭＰ基質で連結したβｉｇ−ｈ３断片ペプチド及びそのリウマチ性関節炎予防及び治療用途
CN111440227B (zh) 一种抑制肿瘤转移及骨肿瘤的多肽及其应用
JP5312025B2 (ja) Ｉｌ−３２モジュレーター
KR20070059009A (ko) 뮤신3 ｅｇｆ-유사 도메인
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
Schröder Studies on molecular properties and functional regulation of terminal leukotriene C4 synthases and cysteinyl-leukotriene receptor signalling in human endothelium
CN1343688A (zh) 人nip2相关蛋白和编码序列及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221122

R150 Certificate of patent or registration of utility model

Ref document number: 7183180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250